Pipeline

Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline of drug candidates in development by our licensees.

Candidate CompoundDevelopment StagePartner

Lenti-D

Indication: Cerebral ALD

Phase II / III

LentiGlobin

Indication: Beta-thalassemia

Phase II / III

LentiGlobin

Indication: Sickle Cell Disease

Phase I / II

bb2121 BCMA

Indication: Multiple Myeloma

Phase I

RetinoStat

Indication: AMD

Phase I

EncorStat

Indication: Corneal Graft

Phase I

Urocortin

Indication: Congestive Heart Failure

Phase II

Available to Partner
CONTACT US

VC-01

Indication: Type I Diabetes

Phase I

alpha-TEA

Indication: Metastic Carinoma, Sarcoma and Lymphoma

Phase I